I have heard that there can still be responses from subsequent treatment with a PD(L)-1 after an initial failure. Curious how widespread that occurrence is (assuming true) and if that could be in play here. The press release noted 3 PRs out of 11 in NSCLC patients with cancer progression following previous treatment with a checkpoint inhibitor. So, what are the odds that there was a prior failure with nivolumab (or another checkpoint inhibitor) but subsequent treatment in this trial resulted in a response that could be solely attributable to nivolumab?
Market Data 
Markets 
AI
